Radiofrequency Ablation of Breast Cancer

A Retrospective Study

Toshikazu Ito, Shoji Oura, Shinji Nagamine, Masato Takahashi, Naohito Yamamoto, Noboru Yamamichi, Mitsuharu Earashi, Hiroyoshi Doihara, Shigeru Imoto, Shoshu Mitsuyama, Kohei Akazawa

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Purpose: To validate the safety and efficacy of percutaneous radiofrequency ablation (RFA) of breast carcinomas. Methods: This retrospective study was conducted by the Breast Cancer Society for Minimally Invasive Therapy following approval from institutional review boards, and with the written informed consent of patients. A total of 386 patients with breast cancer treated with RFA at 10 institutions between July 2003 and June 2009 were identified and included in the analysis. Patients underwent a standard RFA procedure with ultrasound guidance and were followed up every 6 to 12 months. In this study, feasibility of RFA procedure and related safety and ipsilateral breast tumor recurrence (IBTR) were examined. Fisher exact or χ2 test evaluated associations between clinicopathological factors and IBTR, and local recurrence-free survival was estimated using the Kaplan-Meier method. Results: RFA-related adverse events included local pain in 9 patients, skin burns in 15, and nipple retraction in 7. Patients were followed for a median of 50 months. IBTR was more frequently observed in patients with initial tumor sizes > 2 cm (3 of 30, 10%) than in those with initial tumors ≤ 2 cm (8 of 355, 2.3%; P = .015). IBTR-free rates 5 years after RFA were 97%, 94%, and 87% in patients with initial tumor sizes ≤ 1.0 cm, 1.1 to 2.0 cm, and > 2.0 cm, respectively. Conclusions: RFA in breast cancer is a safe and promising minimally invasive treatment for tumors ≤ 2 cm in diameter. Further studies are needed to optimize the technique and evaluate its future role as local therapy.

Original languageEnglish
JournalClinical Breast Cancer
DOIs
Publication statusAccepted/In press - 2017
Externally publishedYes

Fingerprint

Retrospective Studies
Breast Neoplasms
Recurrence
Neoplasms
Safety
Nipples
Research Ethics Committees
Informed Consent
Burns
Therapeutics
Pain
Skin
Survival

Keywords

  • Breast cancer
  • Ipsilateral breast tumor recurrence
  • Local therapy
  • Minimally invasive surgical procedures
  • Radiofrequency ablation

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Ito, T., Oura, S., Nagamine, S., Takahashi, M., Yamamoto, N., Yamamichi, N., ... Akazawa, K. (Accepted/In press). Radiofrequency Ablation of Breast Cancer: A Retrospective Study. Clinical Breast Cancer. https://doi.org/10.1016/j.clbc.2017.09.007

Radiofrequency Ablation of Breast Cancer : A Retrospective Study. / Ito, Toshikazu; Oura, Shoji; Nagamine, Shinji; Takahashi, Masato; Yamamoto, Naohito; Yamamichi, Noboru; Earashi, Mitsuharu; Doihara, Hiroyoshi; Imoto, Shigeru; Mitsuyama, Shoshu; Akazawa, Kohei.

In: Clinical Breast Cancer, 2017.

Research output: Contribution to journalArticle

Ito, T, Oura, S, Nagamine, S, Takahashi, M, Yamamoto, N, Yamamichi, N, Earashi, M, Doihara, H, Imoto, S, Mitsuyama, S & Akazawa, K 2017, 'Radiofrequency Ablation of Breast Cancer: A Retrospective Study', Clinical Breast Cancer. https://doi.org/10.1016/j.clbc.2017.09.007
Ito, Toshikazu ; Oura, Shoji ; Nagamine, Shinji ; Takahashi, Masato ; Yamamoto, Naohito ; Yamamichi, Noboru ; Earashi, Mitsuharu ; Doihara, Hiroyoshi ; Imoto, Shigeru ; Mitsuyama, Shoshu ; Akazawa, Kohei. / Radiofrequency Ablation of Breast Cancer : A Retrospective Study. In: Clinical Breast Cancer. 2017.
@article{3a4da0a1417745c4985c186ed5f69d8b,
title = "Radiofrequency Ablation of Breast Cancer: A Retrospective Study",
abstract = "Purpose: To validate the safety and efficacy of percutaneous radiofrequency ablation (RFA) of breast carcinomas. Methods: This retrospective study was conducted by the Breast Cancer Society for Minimally Invasive Therapy following approval from institutional review boards, and with the written informed consent of patients. A total of 386 patients with breast cancer treated with RFA at 10 institutions between July 2003 and June 2009 were identified and included in the analysis. Patients underwent a standard RFA procedure with ultrasound guidance and were followed up every 6 to 12 months. In this study, feasibility of RFA procedure and related safety and ipsilateral breast tumor recurrence (IBTR) were examined. Fisher exact or χ2 test evaluated associations between clinicopathological factors and IBTR, and local recurrence-free survival was estimated using the Kaplan-Meier method. Results: RFA-related adverse events included local pain in 9 patients, skin burns in 15, and nipple retraction in 7. Patients were followed for a median of 50 months. IBTR was more frequently observed in patients with initial tumor sizes > 2 cm (3 of 30, 10{\%}) than in those with initial tumors ≤ 2 cm (8 of 355, 2.3{\%}; P = .015). IBTR-free rates 5 years after RFA were 97{\%}, 94{\%}, and 87{\%} in patients with initial tumor sizes ≤ 1.0 cm, 1.1 to 2.0 cm, and > 2.0 cm, respectively. Conclusions: RFA in breast cancer is a safe and promising minimally invasive treatment for tumors ≤ 2 cm in diameter. Further studies are needed to optimize the technique and evaluate its future role as local therapy.",
keywords = "Breast cancer, Ipsilateral breast tumor recurrence, Local therapy, Minimally invasive surgical procedures, Radiofrequency ablation",
author = "Toshikazu Ito and Shoji Oura and Shinji Nagamine and Masato Takahashi and Naohito Yamamoto and Noboru Yamamichi and Mitsuharu Earashi and Hiroyoshi Doihara and Shigeru Imoto and Shoshu Mitsuyama and Kohei Akazawa",
year = "2017",
doi = "10.1016/j.clbc.2017.09.007",
language = "English",
journal = "Clinical Breast Cancer",
issn = "1526-8209",
publisher = "Elsevier",

}

TY - JOUR

T1 - Radiofrequency Ablation of Breast Cancer

T2 - A Retrospective Study

AU - Ito, Toshikazu

AU - Oura, Shoji

AU - Nagamine, Shinji

AU - Takahashi, Masato

AU - Yamamoto, Naohito

AU - Yamamichi, Noboru

AU - Earashi, Mitsuharu

AU - Doihara, Hiroyoshi

AU - Imoto, Shigeru

AU - Mitsuyama, Shoshu

AU - Akazawa, Kohei

PY - 2017

Y1 - 2017

N2 - Purpose: To validate the safety and efficacy of percutaneous radiofrequency ablation (RFA) of breast carcinomas. Methods: This retrospective study was conducted by the Breast Cancer Society for Minimally Invasive Therapy following approval from institutional review boards, and with the written informed consent of patients. A total of 386 patients with breast cancer treated with RFA at 10 institutions between July 2003 and June 2009 were identified and included in the analysis. Patients underwent a standard RFA procedure with ultrasound guidance and were followed up every 6 to 12 months. In this study, feasibility of RFA procedure and related safety and ipsilateral breast tumor recurrence (IBTR) were examined. Fisher exact or χ2 test evaluated associations between clinicopathological factors and IBTR, and local recurrence-free survival was estimated using the Kaplan-Meier method. Results: RFA-related adverse events included local pain in 9 patients, skin burns in 15, and nipple retraction in 7. Patients were followed for a median of 50 months. IBTR was more frequently observed in patients with initial tumor sizes > 2 cm (3 of 30, 10%) than in those with initial tumors ≤ 2 cm (8 of 355, 2.3%; P = .015). IBTR-free rates 5 years after RFA were 97%, 94%, and 87% in patients with initial tumor sizes ≤ 1.0 cm, 1.1 to 2.0 cm, and > 2.0 cm, respectively. Conclusions: RFA in breast cancer is a safe and promising minimally invasive treatment for tumors ≤ 2 cm in diameter. Further studies are needed to optimize the technique and evaluate its future role as local therapy.

AB - Purpose: To validate the safety and efficacy of percutaneous radiofrequency ablation (RFA) of breast carcinomas. Methods: This retrospective study was conducted by the Breast Cancer Society for Minimally Invasive Therapy following approval from institutional review boards, and with the written informed consent of patients. A total of 386 patients with breast cancer treated with RFA at 10 institutions between July 2003 and June 2009 were identified and included in the analysis. Patients underwent a standard RFA procedure with ultrasound guidance and were followed up every 6 to 12 months. In this study, feasibility of RFA procedure and related safety and ipsilateral breast tumor recurrence (IBTR) were examined. Fisher exact or χ2 test evaluated associations between clinicopathological factors and IBTR, and local recurrence-free survival was estimated using the Kaplan-Meier method. Results: RFA-related adverse events included local pain in 9 patients, skin burns in 15, and nipple retraction in 7. Patients were followed for a median of 50 months. IBTR was more frequently observed in patients with initial tumor sizes > 2 cm (3 of 30, 10%) than in those with initial tumors ≤ 2 cm (8 of 355, 2.3%; P = .015). IBTR-free rates 5 years after RFA were 97%, 94%, and 87% in patients with initial tumor sizes ≤ 1.0 cm, 1.1 to 2.0 cm, and > 2.0 cm, respectively. Conclusions: RFA in breast cancer is a safe and promising minimally invasive treatment for tumors ≤ 2 cm in diameter. Further studies are needed to optimize the technique and evaluate its future role as local therapy.

KW - Breast cancer

KW - Ipsilateral breast tumor recurrence

KW - Local therapy

KW - Minimally invasive surgical procedures

KW - Radiofrequency ablation

UR - http://www.scopus.com/inward/record.url?scp=85032205577&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85032205577&partnerID=8YFLogxK

U2 - 10.1016/j.clbc.2017.09.007

DO - 10.1016/j.clbc.2017.09.007

M3 - Article

JO - Clinical Breast Cancer

JF - Clinical Breast Cancer

SN - 1526-8209

ER -